Sixth Element Capital
Overview
Sixth Element Capital is a UK-based venture capital firm specializing in early-stage investments in the healthcare sector. The firm manages the £70 million CRT Pioneer Fund, focusing on oncology investments. The firm's investment strategy centers on identifying and supporting innovative companies in the healthcare and health diagnostics industries. By providing capital and strategic guidance, Sixth Element Capital aims to accelerate the development of groundbreaking therapies and diagnostic tools. With a commitment to advancing cancer treatment and diagnosis, Sixth Element Capital collaborates with portfolio companies to bring transformative solutions to market, enhancing patient outcomes and driving progress in the oncology field.
Investment Focus
- Innovative healthcare solutions
- Strong management teams
- Potential for significant impact in oncology
Portfolio Companies
Get the full list of 54,000+ investors
Sixth Element Capital and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about Sixth Element Capital
What sectors does Sixth Element Capital invest in?
Sixth Element Capital invests in Healthcare and Health Diagnostics, and is based in United Kingdom. Sixth Element Capital is listed as a venture capital in the ConnectSafely investor database.
Which regions does Sixth Element Capital invest in?
Sixth Element Capital invests across United Kingdom.
What companies has Sixth Element Capital invested in?
Sixth Element Capital's portfolio includes Achilles Therapeutics, NeoPhore, Azeria Therapeutics, AdoRx Therapeutics and Macrophage Pharma.
Last updated · Source: ConnectSafely investor database
